Thus, this comprehensive analysis gives important novel insights into circulating TAA-specific CD8+ T-cell responses in HCC and clearly highlights severe limitations of these potentially anti-tumoral T cells that may hamper their biological and clinical relevance. The gene discussed is CD8A; the disease is hepatocellular carcinoma.